Clinical trial
BI 2536 Second Line Monotherapy in SCLC
NCT00412880
Study timeline
Study start (actual)2007-02-14Date precision: day
Registry last updated2022-06-22
Observed by CureCurrent2026-10-07
Recorded dates are source observations, not predictions. Missing milestones are not estimated.
Conditions
Carcinoma, Small Cellunresolved
Interventions
BI 2536DRUG
Sponsors & collaborators
Boehringer Ingelheimlead sponsor
Mapped research locations
BostonMassachusetts, United States1ChicagoIllinois, United States1St LouisMissouri, United States1SeattleWashington, United States1CharlestonSouth Carolina, United States1Chapel HillNorth Carolina, United States1EdmontonAlberta, Canada1GreenvilleSouth Carolina, United States1EvanstonIllinois, United States1
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT00412880 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.